Sign up
Pharma Capital

Amryt Pharma agrees Lojuxta distribution deal for Romania and Bulgaria

Dave Allmond, chief commercial officer at Amryt Pharma PLC (LON:AMYT), discusses with Proactive their fourth distribution deal signed in three months for Lojuxta.

Lojuxta treats a very rare, life-threatening genetic condition which causes “bad cholesterol” to accumulate in the body. 

This latest agreement, covering Romania and Bulgaria, is with Romastru Trading, part of the Pharaon Healthcare Europe conglomerate.


View full AMYT profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.